Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2014

Open Access 01-12-2014 | Research article

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

Authors: Charalampos Tzanetakos, Andreas Melidonis, Christos Verras, Georgia Kourlaba, Nikos Maniadakis

Published in: BMC Health Services Research | Issue 1/2014

Login to get access

Abstract

Background

To evaluate the long-term cost-effectiveness of liraglutide versus sitagliptin or exenatide, added to oral antidiabetic drug mono- or combination therapy respectively, in patients with Type 2 diabetes in Greece.

Methods

The CORE Diabetes Model, a validated computer simulation model, was adapted to the Greek healthcare setting. Patient and intervention effects data were gathered from a clinical trial comparing liraglutide 1.2 mg once daily vs. sitagliptin 100 mg once daily, both combined with metformin, and a clinical trial comparing liraglutide 1.8 mg once daily vs. exenatide 10 μg twice daily, both as add-on to metformin, glimepiride or both. Direct costs were reported in 2013 Euros and calculated based on published and local sources. All future outcomes were discounted at 3.5% per annum, and the analysis was conducted from the perspective of a third-party payer in Greece.

Results

Over a patient’s lifetime, treatment with liraglutide 1.2 mg vs. sitagliptin drove a mean increase in discounted life expectancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with liraglutide 1.8 mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19 (0.16) QALYs respectively. As regards lifetime direct costs, liraglutide 1.2 mg resulted in greater costs of €2797 (€1468) versus sitagliptin, and so did liraglutide 1.8 mg compared with exenatide (€1302 [€1492]). Liraglutide 1.2 and 1.8 mg doses were associated with incremental cost effectiveness ratios of €15101 and €6818 per QALY gained, respectively.

Conclusions

Liraglutide is likely to be a cost-effective option for the treatment of Type 2 diabetes in a Greek setting.
Appendix
Available only for authorised users
Literature
1.
Chen L, Magliano DJ, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol. 2012, 8: 228-236.CrossRef
2.
Williams R, Van Gaal L, Lucioni C, Board C-A: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002, 45: S13-S17. 10.1007/s00125-002-0859-9.CrossRefPubMed
3.
Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C: The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabet Med. 2005, 22: 1581-1588. 10.1111/j.1464-5491.2005.01731.x.CrossRefPubMed
4.
5.
Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J: Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med. 2010, 27: 679-684. 10.1111/j.1464-5491.2010.03004.x.CrossRefPubMed
6.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012, 55: 1577-1596. 10.1007/s00125-012-2534-0.CrossRefPubMed
7.
8.
Bode B: An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012, 97: 27-42. 10.1016/j.diabres.2011.12.015.CrossRefPubMed
9.
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004, 20 (Suppl 1): S27-S40.CrossRefPubMed
10.
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004, 20 (Suppl 1): S5-S26.CrossRefPubMed
11.
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M, Group L-D-S: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010, 375: 1447-1456. 10.1016/S0140-6736(10)60307-8.CrossRefPubMed
12.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, Group L-S: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009, 374: 39-47. 10.1016/S0140-6736(09)60659-0.CrossRefPubMed
13.
Liatis S, Thomakos P, Papaoikonomou S, Papazafeiropoulou A, Giannakopoulos N, Karagiaouri E, Sotiropoulos A, Bousboulas S, Melidonis A, Pappas S, Katsilambros N: Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006). Exp Clin Endocrinol Diabetes. 2009, 117: 505-510. 10.1055/s-0029-1225338.CrossRefPubMed
14.
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E, Action in Diabetes 5 met SUSG: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009, 52: 2046-2055. 10.1007/s00125-009-1472-y.CrossRefPubMedPubMedCentral
15.
16.
Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J: Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clin Ther. 2012, 34: 446-456. 10.1016/j.clinthera.2012.01.005.CrossRefPubMed
17.
Souliotis K, Papavasilopoulou M, Konstantinidou C, Spanakis ΑΜ, Apostolakis Μ, Iatrou C: Insurance coverage for the treatment of patients with chronic renal insufficiency. Adoption of economic assessment by the Institute of Social Insurance (IKA). Arch Hell Med. 2009, 26 (5): 668-677.
18.
Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL: Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int J Technol Assess Health Care. 2005, 21: 40-46.CrossRefPubMed
19.
Kourlaba G, Fragoulakis V, Maniadakis N: Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Appl Health Econ Health Policy. 2012, 10: 261-271. 10.2165/11633820-000000000-00000.CrossRefPubMed
20.
Kourlaba G, Fragoulakis V, Maniadakis N: Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy. 2012, 10: 331-342. 10.1007/BF03261867.CrossRefPubMed
21.
Sidiropoulos S: Estimating the Cost of Renal Transplantation in Greece. 2009, Thesis: University of Macedonia, Business Administration Department
22.
23.
Davies MJ, Chubb BD, Smith IC, Valentine WJ: Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012, 29: 313-320. 10.1111/j.1464-5491.2011.03429.x.CrossRefPubMedPubMedCentral
24.
25.
26.
Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D: Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005, 46: 212-221.PubMed
27.
28.
Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M, Group L-D-S: Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012, 35: 1986-1993. 10.2337/dc11-2113.CrossRefPubMedPubMedCentral
29.
Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, Group L-D-S: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011, 65: 397-407. 10.1111/j.1742-1241.2011.02656.x.CrossRefPubMedPubMedCentral
30.
Lee WC, Samyshkin Y, Langer J, Palmer JL: Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012, 15 (Suppl 2): 28-37.CrossRefPubMed
31.
Mezquita Raya P, Perez A, Ramirez de Arellano A, Briones T, Hunt B, Valentine WJ: Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 2013, 4: 417-430. 10.1007/s13300-013-0044-9.CrossRefPubMedPubMedCentral
32.
Lee WC, Conner C, Hammer M: Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther. 2010, 32: 1756-1767. 10.1016/j.clinthera.2010.08.010.CrossRefPubMed
33.
Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M: Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011, 33: 1698-1712. 10.1016/j.clinthera.2011.09.022.CrossRefPubMed
34.
Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559.CrossRefPubMed
35.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360: 129-139. 10.1056/NEJMoa0808431.CrossRefPubMed
36.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572.CrossRefPubMed
Metadata
Title
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
Authors
Charalampos Tzanetakos
Andreas Melidonis
Christos Verras
Georgia Kourlaba
Nikos Maniadakis
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2014
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-14-419

Other articles of this Issue 1/2014

BMC Health Services Research 1/2014 Go to the issue

Research article

A surgeon led smoking cessation intervention in a head and neck cancer centre

Research article

Psychosocial, behavioural and health system barriers to delivery and uptake of intermittent preventive treatment of malaria in pregnancy in Tanzania – viewpoints of service providers in Mkuranga and Mufindi districts

Research article

Factors explaining priority setting at community mental health centres: a quantitative analysis of referral assessments

Research article

Effects of patient health literacy, patient engagement and a system-level health literacy attribute on patient-reported outcomes: a representative statewide survey

Research article

Physicians’ knowledge, beliefs, and use of race and human genetic variation: new measures and insights

Research article

Housing First: exploring participants’ early support needs